Relative Performance
Historical return vs XIC · 2025-06-01–2026-06-01
Edition
Peralta independent valuation · 2026-11-18
12-month target · 2027-11-18
C$99.18
Intrinsic value today
C$94.27
Modeled total return
3.1%
Reference price C$97.58 on 2026-11-18. Total return includes modeled dividends and transaction costs. The target is a valuation checkpoint, not an automatic sale date.
Wait before adding Metro at C$97.58. Our independent 12-month target is C$99.18, offering 3.1% modeled total return. Food recovery and pharmacy growth support earnings, but rent and continued store investment limit cash conversion. A better entry price or stronger recovery and investment returns would improve the case.
Current Price
CAD 97.58
Street Consensus
CAD 101.36
Company details
Sector
Consumer Defensive
Industry
Grocery Stores
Market Capitalization
$20.6B
Primary Exchange
Toronto
Benchmark
XIC - Canada
Status
Watch
Current Price
CAD 97.58
Street Consensus
CAD 101.36
Sector
Consumer Defensive
Industry
Grocery Stores
Market Capitalization
$20.6B
Primary Exchange
Toronto
Benchmark
XIC - Canada
Status
Watch
Wait before adding Metro at C$97.58. Our independent 12-month target is C$99.18, offering 3.1% modeled total return. Food recovery and pharmacy growth support earnings, but rent and continued store investment limit cash conversion. A better entry price or stronger recovery and investment returns would improve the case.
Current Price
CAD 97.58
Street Consensus
CAD 101.36
Sector
Consumer Defensive
Industry
Grocery Stores
Market Capitalization
$20.6B
Primary Exchange
Toronto
Benchmark
XIC - Canada
Status
Watch
The next reported quarterly results can test whether food customers return after the strike and pharmacy growth persists. Conversion-program delivery should make recurring savings visible, while capital spending and lease-adjusted cash conversion show whether earnings recovery reaches shareholders. The dated model checkpoints are analyst review windows, not promised issuer publication dates.
First-year base free cash flow before funded-debt interest is C$886.96 million, versus C$1,027.20 million in the fifth year. The forecast includes net lease cash, normalized taxes, maintenance and growth capital, working capital and a minority cash allowance. Recovery is a level improvement in earnings, while food and pharmacy growth and continued investment determine the longer-term path.
Metro combines recurring grocery demand with a growing pharmacy business, but a durable franchise is not automatically an attractive purchase at any price. At C$97.58, our 12-month target of C$99.18 offers only 3.1% modeled total return. We would wait for a better entry or evidence that recovery and investment productivity exceed our base.
Our independent 12-month target is C$99.18, against current intrinsic value of C$94.27 and a C$97.58 reference quote. Bear and bull targets are C$50.57 and C$188.93 without assigned probabilities. Base total return is 3.1% over the target horizon and 5.7% annualized over five years, including dividends and illustrative costs.
Wait before adding at the reference price. The central return is modest, while a large share of value depends on continuing-business assumptions beyond the explicit forecast. Reassess after food traffic recovery, cash conversion and store-conversion execution improve or the entry price falls. Existing-position sizing belongs to the portfolio decision; this report does not issue a trade.
The latest full-year results show resilient pharmacy sales alongside grocery disruption from the Laval strike. Normal service resumed, but early subsequent food comparable sales remained negative. Store conversions and planned closures aim to improve the cost base. Management’s lost-profit estimate supports a recovery scenario; it is not cash owed back to the company.
The cautious stance could miss faster food recovery, sustained pharmacy growth or investment returns above our estimates. Continued traffic losses, discount competition, wage and supplier inflation or a higher required return would weaken value. Terminal assumptions, tax deductions, maintenance capital and share-award dilution are estimated; target precision should not be confused with forecast certainty.
Historical return vs XIC · 2025-06-01–2026-06-01
The central disagreement is cash conversion rather than whether strike earnings can recover. Store investment, rent and interest consume cash that an adjusted-EPS multiple can obscure. Our base values gradual recovery but charges ongoing reinvestment. The strongest countercase is faster traffic recovery and more productive discount-store expansion, which would lift cash generation beyond this central forecast.
Central case
base
Model confidence
medium
These are conditional operating and valuation cases. A central case does not establish a probability, street consensus or uniquely observed market expectation.
The retained Street median is close to our base target of C$99.18. That numerical proximity does not establish identical operating assumptions, discount rates or analyst probabilities. Our target is derived independently from cash flows.
The C$97.58 quote is closest to our base valuation range. This distance comparison does not uniquely identify market expectations. Recovery optimism, low perceived risk and a durable retail franchise can support different combinations of margin and required return.
The base is the central planning case: gradual strike recovery, continued pharmacy growth, partial competitive margin pressure and funded investment. Its C$99.18 target provides a modest return at the reference quote. Case selection expresses judgment without a measured probability.
Low-to-moderate confidence in target precision reflects estimated capital intensity and a large terminal contribution. The central case is useful for testing decisions, not a statistically calibrated likelihood.
Bear Case
The bear target is C$50.57 with -46.6% modeled total return. Food recovery disappoints, pharmacy growth slows and competitive pressure erodes margin. Less efficient capital spending and a higher required return reduce equity value.
What Must Go Right: Cash generation must still cover the assumed capital program and dividends without new borrowing. The model preserves the annual minimum cash buffer, but does not establish monthly liquidity.
What Must Go Wrong: Customer losses persist after service normalizes, conversions deliver less savings and investment returns fall. A higher refinancing cost and required return compound the operating weakness.
Base Case
The base target is C$99.18 with 3.1% modeled total return. Food demand recovers gradually, pharmacy grows and conversion savings emerge. Competitive pressure limits core margin while maintenance, expansion and working capital remain funded.
What Must Go Right: Food traffic must stabilize, pharmacy remain resilient and capital efficiency support the planned store changes. Strike recovery and savings must reach cash flow rather than be absorbed entirely by higher costs.
What Must Go Wrong: Traffic remains weak, recurring investment exceeds our allowances or lease renewals cost more. Those outcomes would make the terminal margin and growth assumptions too optimistic.
Bull Case
The bull target is C$188.93 with 94.9% modeled total return. Food traffic recovers, pharmacy growth persists and investment becomes more productive. Full strike recovery, timely savings and a lower required return produce a high continuing-business value.
What Must Go Right: Stronger sales and capital efficiency must persist long enough to support the optimistic terminal margin. This case needs both execution and a low required return; a recovery headline alone is insufficient.
What Must Go Wrong: Competitive pressure, higher maintenance needs or a higher required return undermine the case. Its especially large terminal contribution makes the optimistic valuation fragile to those changes.
Peralta independent valuation · 2026-11-18
12-month target · 2027-11-18
C$99.18
Intrinsic value today
C$94.27
Modeled total return
3.1%
Reference price C$97.58 on 2026-11-18. Total return includes modeled dividends and transaction costs. The target is a valuation checkpoint, not an automatic sale date.
Ten-year nominal CAD enterprise cash-flow valuation after net lease cash and funded reinvestment. Funded debt is deducted once. The twelve-month target rolls remaining operating value and the projected cash balance forward; dividends are paid from that cash bridge.
Recurring demand and pharmacy growth support earnings, but normalized cash conversion, store investment and the price paid determine prospective returns. Strike recovery is gradual lost-profit recovery, not reimbursed cash.
Conditional case · no probability assigned
Intrinsic value today
C$47.83
12-month target
C$50.57
12-month total return
-46.6%
Dividends per share
C$1.63
CAD nominal required return
8.00%
Terminal share of cash-flow value
51.7%
Five-year annualized return
-6.4%
Target-date equity bridge
CAD millions: remaining operating value 13,176.6 + cash 553.3 + other assets 0 − funded debt 3,186.7 − other claims 0. Divide by 208.5 million diluted shares to obtain the target. Dividends are added separately for total return.
Conditional case · no probability assigned
Intrinsic value today
C$94.27
12-month target
C$99.18
12-month total return
3.1%
Dividends per share
C$1.63
CAD nominal required return
6.50%
Terminal share of cash-flow value
66.9%
Five-year annualized return
5.7%
Target-date equity bridge
CAD millions: remaining operating value 23,319.9 + cash 543.7 + other assets 0 − funded debt 3,186.7 − other claims 0. Divide by 208.5 million diluted shares to obtain the target. Dividends are added separately for total return.
Conditional case · no probability assigned
Intrinsic value today
C$180.79
12-month target
C$188.93
12-month total return
94.9%
Dividends per share
C$1.63
CAD nominal required return
5.25%
Terminal share of cash-flow value
78.4%
Five-year annualized return
18.9%
Target-date equity bridge
CAD millions: remaining operating value 41,982.8 + cash 591.9 + other assets 0 − funded debt 3,186.7 − other claims 0. Divide by 208.5 million diluted shares to obtain the target. Dividends are added separately for total return.
Conditional five-year stock returns include dividends and illustrative investor costs. They do not establish prospective outperformance of MSCI ACWI IMI CAD net total return over rolling five-year periods. XIC remains the Canadian-sleeve comparator only. No benchmark forecast or trade instruction is implied.
Base-case annualized total return 5.7%. This conditional forecast does not establish outperformance versus MSCI ACWI IMI CAD net total return.
Terminal-growth and discount-rate sensitivities
Discount and terminal-growth shifts are percentage points. Terminal growth funds incremental fixed assets and working capital. The full bear and bull cases also vary sales, margin recovery and investment assumptions.
| Terminal growth shift | Discount shift | 12-month target |
|---|---|---|
| -0.5% | -1.0% | C$120.92 |
| 0.0% | -1.0% | C$131.82 |
| 0.5% | -1.0% | C$146.35 |
| -0.5% | 0.0% | C$93.39 |
| 0.0% | 0.0% | C$99.18 |
| 0.5% | 0.0% | C$106.42 |
| -0.5% | 1.0% | C$75.08 |
| 0.0% | 1.0% | C$78.44 |
| 0.5% | 1.0% | C$82.46 |
Evidence, assumptions and thesis tests
FY2026 results are unaudited. Cash, funded debt and share-award disclosures are September balances; diluted closing shares use a treasury-stock proxy at the November quote. Maintenance capital, tax depreciation, lease renewal and minority distributions are estimates. Annual cash buffers do not test monthly liquidity. Terminal value is material, and no probabilities are assigned.
Financial statements through 2026-09-26. Forecast assumptions are analyst estimates. The terminal value capitalizes a continuing business after funding normalized reinvestment; its contribution is shown for each case.
Review food sales recovery and pharmacy growth at the next reported quarterly results; this is an analyst review window, not a promised publication date.
Test store-conversion execution, capital intensity and whether recurring cost savings are becoming visible.
Persistently negative food comparable sales, loss of customers after the strike, or higher capital spending without improved cash conversion would weaken the base recovery case.
Stronger traffic recovery, sustained pharmacy growth and lower required reinvestment would challenge a cautious valuation.
Reference Price
$97.58
Street Mean Target
$101.36
Price-only Change
+3.9%
Street consensus is a comparison. This price-only change excludes dividends and uses the stored reference price.
Current vs low/median/mean/high target prices
Food and pharmacy sales grow separately, starting at 3.0% and 4.5% in the base forecast. Both fade to 2.0% perpetual nominal growth. These are our estimates: customer traffic had not fully recovered after the strike, and pharmacy strength cannot eliminate grocery competition.
The base gradually recovers 75.0% of management’s estimated strike-related lost earnings. Estimated recurring conversion savings are added separately, reaching C$15.00 million after tax. Core margin faces competitive pressure. Neither recovered profit nor savings is counted twice as an additional margin improvement.
Forecast first-year maintenance capital is C$372.84 million and growth capital C$188.43 million. Incremental working capital absorbs C$28.69 million. The issuer does not disclose the maintenance/growth split; these allowances are estimates anchored to current all-in capital spending. Terminal growth follows the same funding rule rather than assuming costless expansion.
Our nominal CAD WACC is 6.5% in the base, 8.0% in the bear and 5.2% in the bull. These are analyst required-return judgments. A low historical beta does not capture all execution, competition or refinancing risk. The separate sensitivity matrix tests discount-rate and terminal-growth uncertainty.
Terminal value contributes 66.9% of base operating cash-flow value, making normalized margin and reinvestment decisive assumptions. The terminal incremental cash return on fixed investment and working capital is 16.7%; this is a model diagnostic, not disclosed ROIC. Current intrinsic value is C$94.27. The 12-month target of C$99.18 rolls remaining operating value and cash forward after interest and dividends.
Subject percentile rank vs peer set
At the reference quote, equity value plus funded debt less cash is C$23,420.26 million. Against first-year operating cash profit after net recognized rent, this is 12.65x, compared with 12.27x for our modeled enterprise value. This is a consistent cash-rent crosscheck, not reported IFRS EBITDA or a peer fair-value multiple. Street targets remain external context and do not set our target.
Wait for a better entry price or stronger cash evidence at C$97.58. Our independent 12-month target is C$99.18, implying 3.1% total return including dividends and illustrative investor costs. The recovery opportunity is real, but the central return offers little compensation for the model’s terminal-value and execution uncertainty. Faster traffic recovery or lower reinvestment could make this stance too cautious.
No numerical convergence probability is assigned. The target is our cash-flow valuation checkpoint, not a prediction that the market will trade there within the horizon. New evidence can change the cash flows and required return before any convergence occurs.
Confidence in the precise target is low to moderate because maintenance capital, normalized taxes, lease renewals and recovery timing are estimates. Persistent grocery weakness would reduce value; stronger pharmacy growth and productivity would increase it. Quarterly cash conversion and conversion-program delivery test those assumptions more directly than a short-term share-price move.
The company-specific risk case for METRO centres on execution in discount expansion, pharmacy network growth, supply chain reliability, private-label value, loyalty, e-commerce, technology resilience and corporate responsibility commitments. The annual report says medium- and long-term targets assume continued execution of the business, strategic and capital plans; historical inflation; no material macroeconomic, regulatory, competitive, labour, supply-chain or distribution-centre disruptions; effective merchandising and promotions; and efficient operation of distribution centres and stores. Those assumptions are vulnerable to events already visible in the sources, including the Toronto freezer interruption, the Laval produce distribution centre strike, international trade tensions, product shortages, higher production costs and pressure on household budgets. Metro plans nine more Ontario Metro-to-Food Basics conversions and seven new discount stores in FY2027 as it works to rebuild grocery traffic after the Laval dispute. Its plans for pharmacy and discount growth, renovate and expand pharmacy locations, grow rapid delivery and pickup, use the Moi program for personalized promotions, and continue technology and store investments could underperform if customers shift behavior, competitors respond aggressively, systems fail, cyber threats increase, or pharmacy regulation changes. Corporate responsibility execution is also part of the risk profile: the sustainability report identifies product quality and safety, data security, labour relations, customer satisfaction, responsible procurement, climate change, waste, food loss and employee health and safety as material issues, any of which could affect reputation, operations or financial performance.
METRO's food, pharmacy, franchising, employment, privacy, product-safety, environmental, securities and competition obligations create legal and regulatory risk. The annual report states that laws, accounting standards and regulations governing the business are constantly evolving and that new requirements affecting METRO or its franchisees could materially affect performance and sales growth. Prescription drug sales are specifically exposed because the pharmacy activities and pharmacist-owner franchisees operate in regulated areas. Product safety controls are subject to Canadian Food Inspection Agency, MAPAQ, Health Canada and other oversight depending on the activity and jurisdiction. Cybersecurity and data protection carry additional compliance risk because METRO collects confidential information from customers, suppliers, employees, partners, loyalty participants and pharmacy customers. The annual report and AIF disclose ordinary-course proceedings and claims and say litigation outcomes and potential losses are uncertain. Specific disclosed matters include opioid-related class actions involving Pro Doc and Jean Coutu Group, a Canadian Competition Bureau investigation and proposed class actions related to commercial bread, and a Sopropharm proceeding involving Jean Coutu Group franchise agreement provisions. METRO says no provisions for contingent losses were recognized for these matters, but the proceedings remain a risk source until resolved.
Metro ended FY2026 with CAD 110.1 million of cash and an unused CAD 600 million authorized revolving credit facility. Book debt rose to CAD 3.19 billion and lease liabilities totaled CAD 1.79 billion. Operating cash flow fell to CAD 1.56 billion from CAD 1.72 billion, while buybacks and dividends together used over CAD 1 billion. Lower earnings or working-capital pressure would reduce room for investment and shareholder returns. Interest rates, scheduled refinancing, credit exposure to retailers and foreign-currency purchases remain financial risks.
METRO's operating risk is concentrated in food and pharmacy retail across Quebec, Ontario and New Brunswick. The 2025 Annual Information Form describes 1,006 food stores and 638 pharmacies, supported by franchising, wholesale distribution, manufacturing, private brands and loyalty operations. This scale creates exposure to store execution, affiliated merchants, pharmacist-owners, warehouses, distribution centres, manufacturing sites, inventory control, product quality and supplier service levels. The 2025 Annual Report states that product contamination, improper handling, defective or improperly labelled products, recalls and public-health concerns can create liabilities, costs and reputational damage, especially because food products represent the highest proportion of sales. Pharmacy activities add regulatory and professional-standard risk through prescription products, Health Canada oversight and pharmacist-owner operations. Technology is another operating dependency: METRO says virtually all aspects of its business depend on information systems, while online shopping, pharmacy data and the Moi loyalty program increase cyber and privacy exposure. Recent events show the operating sensitivity of the network: the Toronto frozen products distribution centre shutdown caused inventory losses and other direct costs, and the Laval produce distribution labour disruption ended September 24, 2026 after roughly six months. Metro reported restored service levels, while food same-store sales remained negative in the first four weeks of FY2027.
METRO operates in competitive Canadian food and pharmacy retail markets where pricing, banner mix, value perception, store locations, e-commerce, loyalty, labour availability and supplier relationships can affect sales and margins. The 2025 Annual Report identifies intensifying competition, possible new competitors, higher-than-normal cost inflation and changing consumer needs as constant concerns. It also states that increased competition could pressure retail prices and margins, while elevated cost inflation can pressure retail prices, margins and operating costs. METRO's segmentation across Metro and Metro Plus conventional supermarkets, Super C and Food Basics discount banners, Adonis, Premiere Moisson, Jean Coutu, Brunet and pharmacy banners helps address different customer needs, but it also requires continued merchandising, pricing and store investment discipline. Q4 FY2026 food same-store sales fell 1.9%, pharmacy same-store sales rose 5.5% and gross margin fell to 19.2% from 20.0%. The Laval disruption contributed to the food and margin weakness, while new stores supported total sales. Statistics Canada's March 2026 retail release adds industry context: Canadian retail sales increased 0.9%, core retail sales edged down 0.1%, retail sales fell 0.7% in volume terms, Quebec retail sales decreased 0.8%, Ontario retail sales increased 1.4%, and food and beverage retailers increased 0.5%. These mixed indicators show that industry demand can shift by geography, subsector and real volume.
METRO operates a food and pharmacy retail, franchising, distribution and manufacturing model in Canada. The company earns sales from corporate and consolidated food stores and pharmacies, sales of products supplied to affiliated and franchised food retailers, sales of products supplied to franchised pharmacies, generic drug distribution, private brand products, and services provided to retailers and franchisees. Its operating model combines owned stores, franchised and affiliated retailers, pharmacist-owner networks, distribution centres, food preparation plants, private brands, loyalty programs, e-commerce, and banner support services such as merchandising, marketing, retail accounting, store layouts, insurance programs and advisory services.
METRO's cost structure is driven by retail merchandise procurement, pharmacy distribution, food preparation, warehousing, transportation, labour, rent and occupancy, technology, e-commerce, store and pharmacy renovation, depreciation and amortization, financial costs, advertising, loyalty rewards, private brand development, compliance and inventory shrink. The company operates food warehouses for grocery, general merchandise, non-perishable goods, dairy, meat, frozen foods and produce, two distribution centres serving PJC drugstores, and food preparation operations. Metro sold its commercial bakery production activities in Baie-D’Urfé during Q4 FY2026. Q4 FY2026 gross margin was 19.2%, operating expenses were 10.7% of sales and net financial costs were CAD 39.3 million.
Revenue is driven by food and pharmacy sales volumes, food basket inflation, same-store sales, new store openings, banner conversions, store renovations, pharmacy prescription and front-store activity, product assortment and private brand growth, customer loyalty and personalization, online food sales, delivery and pickup services, sales to affiliated and franchised retailers, royalties based on franchised drugstore sales, sales of products supplied to pharmacy owners, services rendered to franchisees and affiliated retailers, and generic drug distribution through Pro Doc. Fiscal 2026 sales rose 2.5% to CAD 22.55 billion. Fourth-quarter sales rose 1.4% to CAD 5.18 billion. New stores supported revenue while the Laval produce distribution labour disruption weighed on the Quebec food network.
Metro Inc. is a Canadian company headquartered at 11011 Maurice-Duplessis Boulevard in Montreal, Quebec, with shares listed on the Toronto Stock Exchange under MRU. METRO has a history dating back to 1947 and is a leader in the food and pharmacy industry in Quebec and Ontario. With annual sales of more than $22 billion, the company operates as a retailer, franchisor, manufacturer and distributor. As of September 27, 2025, METRO, its franchisees and affiliated retailers operated 1,006 food stores and 638 pharmacies, including Metro, Metro Plus, Super C, Food Basics, Adonis, Premiere Moisson, PJC Jean Coutu, PJC Sante, PJC Sante Beaute, Brunet, Brunet Plus, Brunet Clinique, Clini Plus, Metro Pharmacy and Food Basics Pharmacy.
METRO's activities are concentrated in Quebec, Ontario and New Brunswick. In food retail, its stores operate in Quebec, Ontario and New Brunswick across conventional, discount, neighbourhood and specialty formats. In pharmacy retail, Jean Coutu and Brunet networks operate primarily in Quebec, with additional PJC drugstores in Ontario and New Brunswick, while Metro Pharmacy and Food Basics Pharmacy operate in Ontario. The company also sells Pro Doc generic drugs mostly in Quebec through the Jean Coutu Group and McMahon. Its operational footprint includes distribution centres and food preparation assets in Quebec and Ontario, including automated fresh and frozen distribution investments in Terrebonne, Laval and Toronto.
Key operating levers include same-store food sales, same-store pharmacy sales, online food sales, prescription and front-store pharmacy sales, new store openings, banner conversions, store and pharmacy renovations, private brand penetration and product innovation, loyalty membership and customer personalization, e-commerce pickup and delivery capacity, supply chain efficiency, product availability, food basket inflation, gross margin, operating expenses as a percentage of sales, shrink, distribution centre productivity and labour stability. In Q4 FY2026, food same-store sales fell 1.9%, pharmacy same-store sales rose 5.5% and online food sales rose 3.3%. Four discount stores opened in the quarter, including one conversion.
METRO offers food, pharmacy, health and beauty, over-the-counter medication, general merchandise, ready-to-eat meals, bakery, pastry, deli products, private brand products, generic drugs, pharmacy services and e-commerce services. Its private brands include Irresistible, Selection, Life Smart, Personnelle, Lucky Koi, Harvest Best, Premiere Moisson, Adonis, Phoenicia, Cedar, PJC Jean Coutu, PJC Delices and Pro Doc. The food network includes conventional supermarkets, discount stores, Mediterranean and Middle Eastern specialty stores, neighbourhood stores and artisan bakery and deli stores. The pharmacy network includes franchised PJC and Brunet stores, corporate and franchise Ontario pharmacies, expanded pharmacist consultations, prescription pickup lockers and online pharmacist appointment functionality.
METRO reaches customers through a segmented banner network of conventional supermarkets, discount stores, neighbourhood grocery stores, specialty food stores and pharmacies. Its food banners include Metro, Metro Plus, Super C, Food Basics, Adonis, Marche Richelieu, Marche Ami and Premiere Moisson, while its pharmacy banners include PJC Jean Coutu, PJC Sante, PJC Sante Beaute, Brunet, Brunet Plus, Brunet Clinique, Clini Plus, Metro Pharmacy and Food Basics Pharmacy. The company supplies corporate, franchised and affiliated stores from owned and affiliated distribution centres, provides services and commercial programs to retailers and franchisees, and extends its customer reach through the Moi loyalty program, mobile applications, personalized communications, click-and-collect, delivery partnerships with DoorDash, Instacart and Uber, smart prescription lockers and online pharmacist appointment tools.
METRO operates in competitive food and pharmacy markets where intensifying competition, potential new competitors, cost inflation and changing consumer needs can pressure retail prices, margins and operating costs. Its operating activities require government permits and licences, including for alcoholic beverages, tobacco, lottery tickets, pharmaceutical products and medical devices. Certain food and health products are subject to price regulation, including prescription drugs, milk, beer and wine. Food safety and pharmaceutical safety are important operating requirements: suppliers, distribution centres and stores must comply with applicable standards and regulations, including oversight by authorities such as the Canadian Food Inspection Agency, MAPAQ, Health Canada and professional pharmacy standards. The company also monitors climate, supply chain, labour, human rights and responsible procurement obligations, including requirements under the Fighting Against Forced Labour and Child Labour in Supply Chains Act.
Metro is a Canadian food and pharmacy retailer, franchisor, distributor, and manufacturer focused mainly on Quebec, Ontario, and New Brunswick. The 2025 AIF says Metro has a history going back to 1947 and is a leader in the food and pharmacy retailing industry with more than 1,600 retail outlets in Canada and annual sales of more than $22 billion. As of September 27, 2025, Metro, its franchisees, and affiliated retailers operated 1,006 food stores and 638 pharmacies. The food network includes Metro, Metro Plus, Super C, Food Basics, Adonis, Marche Richelieu, Marche Ami, Les 5 Saisons, and Premiere Moisson formats across supermarkets, discount stores, neighborhood stores, and specialty stores. The pharmacy network includes PJC Jean Coutu, PJC Sante, PJC Sante Beaute, Brunet, Brunet Plus, Brunet Clinique, Clini Plus, Metro Pharmacy, and Food Basics Pharmacy. Metro's activities include food retailing and distribution, pharmacy franchising and wholesaling, drug distribution through Pro Doc, food manufacturing and preparation, private brands, loyalty, e-commerce, and support services for affiliated retailers, franchisees, and pharmacist-owners.
Metro operates in a highly competitive Canadian food and pharmacy retail market where consumer value, location, assortment, service, pricing, digital convenience, and banner format all matter. The AIF identifies intensifying competition, possible new competitors, higher-than-normal cost inflation, and changing consumer needs as continuing concerns. It also states that increased competition could pressure retail prices and margins, while higher cost inflation could pressure retail prices, margins, and operating costs. Metro responds through store investments, merchandising programs, private label offerings, supply-chain work with partners, and market segmentation across conventional Metro supermarkets, Super C and Food Basics discount banners, Adonis Mediterranean stores, Premiere Moisson specialty stores, and a pharmacy network under Jean Coutu, Brunet, Metro Pharmacy, and Food Basics Pharmacy. The annual report describes a 2025 environment marked by international trade tensions, rising costs for some products, rising unemployment, high food CPI, and stronger consumer search for value. StatCan's March 2026 retail release showed Canadian retail sales up 0.9% month over month, core retail down 0.1%, and food and beverage retailers up 0.5%, led by a 0.8% increase at supermarkets and other grocery retailers excluding convenience retailers.
Metro positions itself as a leader in Quebec and Ontario food and pharmacy retailing through a dense multi-format network and integrated pharmacy presence. The AIF states that Metro is a leader in the food and pharmacy industry in Quebec and Ontario, and the annual report company profile repeats that Metro is a food and pharmacy leader in those provinces. As of September 27, 2025, the network included 710 food stores in Quebec, 289 in Ontario, and 7 in New Brunswick, plus 526 pharmacies in Quebec, 85 in Ontario, and 27 in New Brunswick. The AIF says the Jean Coutu Group is the largest pharmacy chain in Quebec and that its PJC network included 419 drugstores across Quebec, Ontario, and New Brunswick, while Brunet added 141 drugstores. Metro's 2025 operational actions reinforced this positioning through five new Food Basics stores in Ontario, seven new Super C stores in Quebec including five conversions from Metro stores, one Metro store, one Adonis store, two Jean Coutu pharmacies, one Metro Pharmacy, and major renovations or expansions across food and pharmacy locations. The annual report also notes that Metro uses key performance indicators including number of stores, store square footage growth, customer satisfaction, and market share.
Metro sits between a broad supplier base and consumers, affiliated retailers, franchisees, and pharmacist-owners. The AIF states that Metro continuously evaluates its supply chain, including distribution methods, facilities, technologies, transportation modes, and supplier relationships, to maintain a cost-efficient supply system. It also states that Metro is not dependent on a single supplier or a small number of suppliers, holds sufficient inventories to support product availability, maintains relationships with many national and regional suppliers, and can turn to another supplier reasonably quickly if a supplier service breakdown occurs. Food stores are supplied by owned warehouses for grocery products, general merchandise, non-perishables, dairy, meat, frozen foods, produce, and neighborhood grocery products; Adonis and Premiere Moisson use additional distribution centres and food preparation plants; PJC and Brunet pharmacies are supported by Jean Coutu Group and McMahon wholesaling and distribution. Customers include grocery shoppers, loyalty members, online grocery users, pharmacy patients, and consumers seeking health, beauty, over-the-counter, cosmetic, baby, prepared-food, bakery, discount, conventional, and specialty offerings. The Moi program reached almost five million customers, and Metro expanded one-hour delivery, Click & Collect, Instacart, pharmacy marketplace delivery, pharmacist appointments, and prescription pickup lockers.
Metro's source-supported advantages are scale in Quebec and Ontario, multi-banner segmentation, pharmacy franchising and distribution, private brands, loyalty, e-commerce capability, and supply chain infrastructure. The AIF describes Metro as a leader in the food and pharmacy industry in Quebec and Ontario, with more than $22 billion of annual sales, 1,006 food stores, and 638 pharmacies. Its banners address conventional grocery, discount grocery, Mediterranean food, bakery and prepared foods, neighborhood formats, and large, medium, and small pharmacies. Metro's private brand portfolio includes premium, value, health-oriented, health and beauty, over-the-counter, cosmetics, baby, ethnic, bakery, and generic drug offerings, with more than 350 new grocery private brand products and 290 new pharmacy private brand products launched in 2025. The Moi loyalty program reached almost five million customers across Quebec, Ontario, and New Brunswick, supporting personalized promotions across food and pharmacy banners. The annual report adds that Metro invested in discount store openings, pharmacy renovations, delivery, pickup, smart lockers, pharmacist services, and supply chain efficiency, while reporting 2025 gross margin improvement partly from food distribution productivity and store shrink improvement.
Metro's industry is built around recurring food and pharmacy demand, but growth and margins still move with consumer budgets, inflation, trade conditions, prescription volumes, store investment, and digital adoption. The AIF states that, other than holiday periods that correlate with higher sales, Metro does not have significant seasonality. The annual report states that fiscal 2025 sales were $22.0067 billion, up 3.7%, driven by higher sales in the discount and pharmacy retail networks; food same-store sales increased 2.4%, online food sales increased 18.5%, and pharmacy same-store sales increased 5.6%, including a 6.7% increase in prescription drugs. Management also described high food CPI, pressure on household budgets, rising unemployment, and a strong consumer search for value. StatCan's March 2026 retail release showed Canadian retail sales up 2.1% in the first quarter of 2026, with volume sales up 1.2%, while March core retail sales edged down 0.1%. The same release showed food and beverage retailers up 0.5% in March, with supermarkets and other grocery retailers excluding convenience retailers up 0.8%, indicating that grocery can grow even when broader core retail is softer.
Metro's pricing and cost position is shaped by intense competition, food inflation, supplier costs, private labels, store productivity, distribution efficiency, shrink, and pharmacy reimbursement dynamics. The AIF says increased competition could pressure retail prices and margins, while higher-than-normal cost inflation could pressure retail prices, margins, and operating costs. It also states that Metro uses merchandising programs, a strong private label offer, and work with supply chain partners to mitigate cost inflation impacts. The annual report describes 2025 pressure from international trade tensions, shortages, increased production costs, high food CPI, and household budget pressure, with meat, coffee, and fresh vegetables among categories affected. At the same time, the annual report reports fiscal 2025 gross margin of 19.9% compared with 19.7% in fiscal 2024, with improvement partly attributable to food distribution centre productivity gains and shrink improvement in stores. Metro also uses discount banners, conventional banners, specialty banners, private labels, and Moi loyalty promotions to address value-seeking customers. In pharmacy, regulated prescription drugs and professional services create a distinct pricing environment, while the AIF notes prescription drugs are among the products subject to price regulation.
Metro's industry has meaningful operating barriers from store networks, banner rights, real estate, distribution infrastructure, food safety controls, pharmacy regulation, private brand development, loyalty data, franchise services, and supplier relationships. The AIF states that Metro operates or services 1,006 food stores and 638 pharmacies, that its food retail network is supplied by owned warehouses and food preparation plants, and that PJC and Brunet pharmacy franchisees are supported by centralized purchasing, marketing, training, human resources, operational consulting, information systems, and private label programs. Metro also grants banner operating rights at its discretion and requires retailers to meet criteria before using its banners. Substitutes and competitive alternatives remain broad: consumers can shop conventional supermarkets, discount grocery stores, Mediterranean and specialty formats, neighborhood stores, pharmacy banners, mass merchants, digital grocery options, delivery marketplaces, and other health and beauty channels. Metro's own segmentation across Metro, Super C, Food Basics, Adonis, Premiere Moisson, Jean Coutu, Brunet, Metro Pharmacy, and Food Basics Pharmacy reflects that customers can shift among formats when value, convenience, product mix, or service expectations change.
Metro's industry is structurally regulated and operationally exposed to food safety, pharmacy oversight, product pricing rules, labor relations, supply chain disruption, technology, cybersecurity, climate, and evolving corporate responsibility expectations. The AIF states that Metro requires government permits and licences for activities including alcohol, tobacco, lottery tickets, pharmaceutical product distribution, and medical devices, and that some food and health products are subject to price regulation, including prescription drugs, milk, beer, and wine. The annual report says food and pharmaceutical safety risks include contamination, improper handling, defective or improperly labelled products, manufacturing, packaging, labelling, in-store preparation, warehousing, and distribution. It also states that food suppliers must meet applicable regulatory oversight, distribution centres and stores have food safety programs, and pharmacy distribution is subject to Health Canada oversight while pharmacists must meet professional standards. Other risks include prescription drug sales regulation, changing laws and accounting standards, potential work stoppages among unionized store and distribution employees, supplier service breakdowns, distribution-centre interruption, cyberattacks, confidential customer and pharmacy data, climate risks affecting operations and suppliers, and higher fuel, energy, and utility costs.
Capital structure composition and liquidity ratios
At September 26, 2026, cash was C$110.1 million. Current and long-term funded debt totaled C$3,186.7 million, separate from C$1,787.9 million of recognized lease liabilities. Finance-sublease receivables totaled C$469.2 million. These are reporting-date balances, rather than a November cash or debt update. The unused C$600 million revolving facility provides contractual liquidity subject to its terms; it is not cash or unencumbered funding.
The strike ended on September 24 and normal service resumed, although food comparable sales remained negative in the first four weeks of FY2027. Management plans seven new discount stores in FY2027. The conversion and closure program includes ten Metro-to-Food Basics conversions and is expected to finish by the end of FY2027; management estimates C$15 million of recurring net earnings benefit by the end of FY2028. These are management plans and estimates, rather than completed savings or assured sales recovery.
Revenue (CAD) and profitability margins (% of revenue)
FY2026 sales were C$22,548.7 million, up from C$22,006.7 million. Food sales were C$17,399.1 million and pharmacy sales C$5,149.6 million. Fourth-quarter food comparable sales fell 1.9%, while pharmacy comparable sales rose 5.5%. Adjusted net earnings were C$949.6 million and adjusted diluted EPS C$4.48, down 6.1%. The company estimates the Laval strike reduced full-year net earnings by C$97 million and EPS by C$0.48; that disruption remains within its adjusted earnings measure.
Operating, investing, and financing cash flow by period
FY2026 operating cash flow of C$1,561.4 million includes C$130.1 million of working-capital use and C$361.6 million of income taxes paid. Fixed and intangible capital spending totaled C$456.6 million. Deducting that spending, C$134.9 million of funded-debt interest, C$285.4 million of lease principal and C$56.2 million of lease interest, then adding C$99.9 million of finance-sublease principal receipts and C$13.8 million of interest receipts, leaves C$742.0 million before other investments, borrowing and common shareholder returns. This analyst cash bridge differs from the C$819.4 million subtotal that deducts capital spending and lease principal alone; it is not a company-defined free-cash-flow measure.
Sales increased 2.5% in FY2026, but the strike and grocery trading conditions weighed on earnings. Pharmacy remained the stronger source of comparable-sales growth. Period comparisons should distinguish the operating disruption from asset disposals, restructuring and impairment charges. A recovery in lost earnings is a counterfactual operating improvement; it does not create a cash receivable or refund.
Adjusted diluted EPS was C$4.48 versus GAAP diluted EPS of C$4.18. Operating profit was C$1,342.0 million. Adding depreciation and amortization, restructuring and impairment, then removing disposal gains, gives C$1,994.7 million of recurring operating profit before recognized lease cash, an analyst subtotal equal to about 8.85% of sales. It retains compensation expense. Food and pharmacy revenue are disclosed separately, but separate profit margins are not; assigning segment margins would require estimates.
Common dividends of C$335.7 million and repurchases of C$696.5 million exceeded the C$742.0 million cash bridge. Funded borrowing of C$594.8 million less C$367.5 million of repayments supplied C$227.3 million, while disposals and other investing flows also affected cash. This is not evidence of a financing failure, but it prevents assuming buybacks were entirely funded by recurring post-lease cash. Debt maturities and renewed borrowing costs remain relevant to future distribution capacity.
Restructuring, impairment and asset-disposal gains complicate the FY2026 trend. Commercial-bakery and other property proceeds are separate investing receipts and should not be extrapolated as recurring operating cash. The prior audited lease notes distinguish recognized lease principal and interest from variable and short-term rent already expensed in operations. Any continuing-business cash analysis should fund renewed leases and replacement investment, rather than assume expiring contract schedules make occupancy free.
Cash-flow reconciliation starts with C$1,177.6 million of pretax income, adds C$625.2 million of depreciation and amortization, C$25.7 million of restructuring, C$33.9 million of impairment, C$14.3 million of share compensation, C$44.1 million of pension cash timing and C$164.4 million of net finance costs, and deducts C$32.1 million of asset gains before working capital and taxes. Noncash charges must not be added again after starting from reported operating cash flow. Treating share compensation as an economic cost reduces the C$742.0 million cash bridge to C$727.7 million; also removing the pension cash-timing benefit gives C$683.6 million. Those are analyst diagnostic adjustments, not GAAP earnings or issuer guidance.
| P/B | P/E | P/S | Peer Set | EV/EBITDA | EV/Revenue | Market Cap | Forward P/E | Company Name | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|
| 8.88 | 35.40 | 0.55 | WN | 9.29x | 0.98x | $36.0bn | 17.69 | George Weston Limited | $63.5bn |
| 1.93 | 27.41 | 1.09 | L | 6.62x | 0.59x | $70.5bn | 21.08 | Loblaw Companies Limited | $37.9bn |
| 2.51 | 26.39 | 0.88 | SAP | 12.40x | 1.05x | $16.7bn | 18.44 | Saputo Inc. | $20.0bn |
| 33.05 | 37.29 | 6.62 | DOL | 29.14x | 7.43x | $48.0bn | 30.26 | Dollarama Inc. | $53.9bn |
| 3.72 | 18.70 | 0.83 | 14.51x | 1.22x | $18.5bn | 15.75 | Subject (MRU) | $27.1bn |
| ROA | ROE | Peer Set | Net Margin | Company Name | Gross Margin | Operating Margin |
|---|---|---|---|---|---|---|
| 6.9% | 19.4% | WN | 1.8% | George Weston Limited | 32.0% | 7.8% |
| 7.1% | 24.5% | L | 4.3% | Loblaw Companies Limited | 31.3% | 7.0% |
| 5.1% | 9.4% | SAP | 3.4% | Saputo Inc. | 9.2% | 6.9% |
| 15.5% | 99.0% | DOL | 18.0% | Dollarama Inc. | 45.0% | 24.5% |
| 6.2% | 13.9% | 4.4% | Subject (MRU) | 19.7% | 6.8% |
| All numbers in thousands except per-share amounts (CAD) | Sep 2026 | Sep 2025 |
|---|---|---|
| Total Revenue | 22,548,700 | 22,006,700 |
| Cost of Revenue | 18,177,800 | 17,636,400 |
| Gross Profit | 4,370,900 | 4,370,300 |
| Operating Expenses | 3,028,900 | 2,906,300 |
| Operating Income | 1,342,000 | 1,464,000 |
| Finance and Other Costs | 164,400 | 143,800 |
| Pretax Income | 1,177,600 | 1,320,200 |
| Income Tax Expense | 291,500 | 300,700 |
| Net Income | 886,100 | 1,019,500 |
| Net Income Attributable to Parent | 883,900 | 1,017,000 |
| All numbers in thousands except per-share amounts (CAD) | 12 Weeks Ended 2026-09-26 | 12 Weeks Ended 2025-09-27 | 52 Weeks Ended 2026-09-26 | 52 Weeks Ended 2025-09-27 |
|---|---|---|---|---|
| Total Revenue | 5,179,500 | 5,108,700 | 22,548,700 | 22,006,700 |
| Cost of Revenue | 4,185,700 | 4,086,900 | 18,177,800 | 17,636,400 |
| Gross Profit | 993,800 | 1,021,800 | 4,370,900 | 4,370,300 |
| Operating Expenses | 685,100 | 701,400 | 3,028,900 | 2,906,300 |
| Operating Income | 308,700 | 320,400 | 1,342,000 | 1,464,000 |
| Finance and Other Costs | 39,300 | 34,400 | 164,400 | 143,800 |
| Pretax Income | 269,400 | 286,000 | 1,177,600 | 1,320,200 |
| Income Tax Expense | 67,500 | 69,000 | 291,500 | 300,700 |
| Net Income | 201,900 | 217,000 | 886,100 | 1,019,500 |
| Net Income Attributable to Parent | 200,800 | 216,000 | 883,900 | 1,017,000 |
| All numbers in thousands except per-share amounts (CAD) | Sep 2026 | Sep 2025 |
|---|---|---|
| Current Assets | 2,832,700 | 2,661,000 |
| Non-current Assets | 11,898,800 | 11,878,400 |
| Total Assets | 14,731,500 | 14,539,400 |
| Current Liabilities | 2,046,000 | 2,053,800 |
| Non-current Liabilities | 5,788,700 | 5,440,500 |
| Total Liabilities | 7,834,700 | 7,494,300 |
| Stockholders Equity | 6,896,800 | 7,045,100 |
| Cash And Cash Equivalents | 110,100 | 67,300 |
| Debt | 3,186,700 | 2,955,300 |
| All numbers in thousands except per-share amounts (CAD) | As At 2026-09-26 | As At 2025-09-27 |
|---|---|---|
| Current Assets | 2,832,700 | 2,661,000 |
| Non-current Assets | 11,898,800 | 11,878,400 |
| Total Assets | 14,731,500 | 14,539,400 |
| Current Liabilities | 2,046,000 | 2,053,800 |
| Non-current Liabilities | 5,788,700 | 5,440,500 |
| Total Liabilities | 7,834,700 | 7,494,300 |
| Stockholders Equity | 6,896,800 | 7,045,100 |
| Cash And Cash Equivalents | 110,100 | 67,300 |
| Debt | 3,186,700 | 2,955,300 |
| All numbers in thousands except per-share amounts (CAD) | Sep 2026 | Sep 2025 |
|---|---|---|
| Operating Cash Flow | 1,561,400 | 1,724,900 |
| Investing Cash Flow | -238,500 | -408,600 |
| Financing Cash Flow | -1,280,100 | -1,278,400 |
| Effect Of Exchange Rate Changes | 0 | 0 |
| Change In Cash | 42,800 | 37,900 |
| Beginning Cash Position | 67,300 | 29,400 |
| End Cash Position | 110,100 | 67,300 |
| Capital Expenditure | 456,600 | 510,600 |
| All numbers in thousands except per-share amounts (CAD) | 12 Weeks Ended 2026-09-26 | 12 Weeks Ended 2025-09-27 | 52 Weeks Ended 2026-09-26 | 52 Weeks Ended 2025-09-27 |
|---|---|---|---|---|
| Operating Cash Flow | 436,400 | 499,100 | 1,561,400 | 1,724,900 |
| Investing Cash Flow | -48,300 | -183,200 | -238,500 | -408,600 |
| Financing Cash Flow | -327,900 | -324,200 | -1,280,100 | -1,278,400 |
| Effect Of Exchange Rate Changes | 0 | 0 | 0 | 0 |
| Change In Cash | 60,200 | -8,300 | 42,800 | 37,900 |
| Beginning Cash Position | 49,900 | 75,600 | 67,300 | 29,400 |
| End Cash Position | 110,100 | 67,300 | 110,100 | 67,300 |
| Capital Expenditure | 142,100 | 190,000 | 456,600 | 510,600 |
| Value | Shares | Holder Type | Shareholder | Date Reported | Percentage Out |
|---|---|---|---|---|---|
| 254,478,742 | 2,910,657 | mutual_fund | Fidelity Investment Trust-Fidelity Series Canada Fund | Mar 2026 | 1.38% |
| 251,565,312 | 2,877,334 | mutual_fund | VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | Jan 2026 | 1.36% |
| 160,442,968 | 1,835,102 | mutual_fund | VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | Dec 2025 | 0.87% |
| 108,706,090 | 1,243,350 | mutual_fund | Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund | Feb 2026 | 0.59% |
| 79,791,153 | 912,629 | mutual_fund | Fidelity Concord Street Trust-Fidelity SAI Canada Equity Index Fund | Mar 2026 | 0.43% |
| 72,504,999 | 829,292 | mutual_fund | Fidelity Devonshire Trust-Fidelity Equity-Income Fund | Mar 2026 | 0.39% |
| 65,524,850 | 749,455 | mutual_fund | J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Canada ETF | Jan 2026 | 0.36% |
| 48,428,176 | 553,908 | mutual_fund | DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | Jan 2026 | 0.26% |
| 46,430,575 | 531,060 | mutual_fund | Variable Insurance Products Fund-VIP Equity-Income Portfolio | Mar 2026 | 0.25% |
| 37,920,052 | 433,719 | mutual_fund | VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Index Fd. | Jan 2026 | 0.21% |
| 6,932,237 | 79,289 | institutional | Mn Services Vermogensbeheer B.V. | Mar 2026 | 0.04% |
METRO's social factors include customers, colleagues, health and safety, equity, diversity and inclusion, responsible procurement, human rights, communities and food security. The 2025 Corporate Responsibility Report describes METRO as a food and pharmacy leader in Quebec and Ontario, operating or servicing 1,006 food stores and 638 pharmacies, with more than 97,000 colleagues working directly or indirectly for METRO and more than 53,000 working directly for METRO. The report says ED&I is integrated into human resources processes, including hiring, onboarding, training and recruitment partnerships that reach newcomers, asylum seekers, women from diverse backgrounds, newly arrived workers, people with intellectual disabilities and autistic people. It also reports the Maurice-Pollack Award for ethnocultural diversity management and recognition among Montreal's Top Employers and Canada's Top Employers for Young People. Health and safety priorities include harmonized processes across Quebec and Ontario, ergonomics and injury prevention, incident management, accident investigations, safety interaction programs, Detect & Correct in retail stores, stronger safety training and mental-health training. Community impact includes PRISM certification from Imagine Canada for donating at least 1% of pre-tax profits to local communities, food and money donations to organizations and food banks, the One More Bite program, food rescue apps, shared kitchens, support for health-care access, and community investments intended to reduce inequalities related to food and health.
METRO's corporate responsibility governance is integrated into management and overseen by the Board of Directors. The 2025 Corporate Responsibility Report states that the Board oversees activities and disclosure related to corporate responsibility, including ESG matters, through the Governance and Corporate Responsibility Committee, and also approves corporate responsibility plans and reports. The Executive Committee approves the corporate responsibility strategy, aligns priorities with business strategy and incentive plans for relevant executives and employees, and monitors objectives. The Vice President, Public Affairs and Communications develops strategic corporate responsibility directives and reports progress to the Executive Committee and the Governance and Corporate Responsibility Committee. In-house teams report to the vice presidents responsible for CR Plan programs, and specific working groups or committees support environment, climate change, equity, diversity and inclusion, responsible procurement, packaging and printed materials, and health and safety. The Annual Information Form repeats this governance structure and says the Board approves corporate responsibility plans and reports. The proxy circular describes 91% independent director nominees, 45% women director nominees, separation of the CEO and Chair roles, annual director elections, a Directors' Code of Ethics, majority voting, annual Board-effectiveness assessment, shareholder engagement, Board oversight of ESG matters and climate risk, and Board oversight of operational risks including cybersecurity.
METRO reports environmental factors through its 2025 Corporate Responsibility Report, which covers the 2025 fiscal year ended September 27, 2025 and is aligned to SASB Food Retailers & Distributors, SASB Drug Retailers and GRI Standards. Environmental priorities include climate change, waste, food loss and waste, responsible procurement, packaging and printed materials, and supplier practices. METRO reports that Scopes 1 and 2 greenhouse gas emissions received limited assurance from its external auditor and that Scopes 1 and 2 emissions decreased 2.9% versus the 2023 baseline year. The company maintains five near-term GHG reduction objectives while no longer pursuing SBTi validation because of the broader FLAG deforestation scope required by SBTi. Refrigeration is a key focus because refrigerant leaks are the largest contributor to direct GHG emissions; in 2025, METRO completed 54 refrigeration projects, including conversions to lower-GWP gases and refurbishments of aging equipment. Waste controls include store-level and distribution-centre diversion programs, an Environment Ambassador pilot, organics recovery, recycling, food donations, food rescue apps and improved sorting. The report states that the 2025 store diversion rate reached 78.5%, distribution and production centres reached an 89% diversion rate, and METRO reduced the food loss and waste ratio in stores by 27% versus its 2016 baseline.
METRO's ESG risks and opportunities are tied to food and pharmacy retail operations, supply chain resilience, climate transition, refrigerant management, waste diversion, food loss and waste, food security, responsible procurement, human rights, data security, health and safety, labour availability, regulatory change and reputation. The 2025 Annual Report says risks that could affect performance include supply chain, distribution centre or technology disruptions, material labour shortages or conflicts, and events that significantly damage brand or reputation. The Annual Information Form incorporates the Annual Report's risk-management section and states that competitive pressures, cost inflation, changing consumer needs and supply-chain efficiency are constant concerns. ESG-specific risk factors include the evolving regulatory landscape for human rights, supplier social and environmental standards, Scopes 1 and 2 climate assurance, food waste reduction, corporate donations, professional inclusion and community investment. The 2025 Corporate Responsibility Report identifies data security, climate change, food waste, waste, equity, diversity and inclusion, packaging and printed materials, responsible procurement and human rights as material topics. Opportunities in the selected sources include stronger supplier assessment through Sphera, continuous improvement plans for suppliers below METRO's compliance threshold, an updated Supplier Code of Conduct, a first Human Rights Statement, food rescue partnerships, community investment, fast-charging infrastructure at store locations, and ESG objectives in executive long-term incentives.
No sources are listed for this edition.
| Worksheet | Output |
|---|---|
| Reproduce archived values | Recorded values |